CVRx Inc (CVRX) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of CVRx Inc stock $1.36, price $0.87, upside +56.5%, quality 40 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $0.8690 – $33.01 · fair‑value band $0.9000 – $1.70 · the $0.8690 price screens below the $1.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow CVRx in your weekly email
Every Wednesday you see whether CVRx is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally.
Show moreShow less
The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system.
It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Stock analysis
CVRx Inc (CVRX) currently trades at $0.8690, while our model-based Fair Value estimate is $1.36, implying the stock looks roughly 36% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.9000 (bear) to $1.70 (bull), the price of $0.8690 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
CVRx Inc reported revenue of $56.7M in FY2025 versus $13.0M in FY2021, a compound +44.4%/yr. Reported net income was −$53.3M in FY2025.
Key figures
Market cap $23.0M Micro · P/S ratio 0.38 · EPS (TTM) $−2.00 · Net margin −88.3% · Return on equity −172% · Return on assets (EBIT) −36.4% (5-year average) · Operating margin −94.3% · Revenue (TTM) $60.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 91% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 57%, CVRX screens cheaper than that median.
Fair Value models
Bear$0.9000Fair Value $1.36Bull$1.70
Price $0.8690 · Upside +56.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director bought shares worth $76,309, on Aug 13, 2026. Over the same period, one person sold shares worth $3,338.
BuyBrent BinkowskiCHIEF OPERATING OFFICER26,223 shares at $2.91$76,309Aug 13, 2026
SaleBrent BinkowskiCHIEF OPERATING OFFICER1,309 shares at $2.55$3,338Aug 12, 202610b5-1 plan
SalePhilip B. AdamsonChief Medical Officer1,262 shares at $7.90$9,970Mar 2, 202610b5-1 plan
SaleKevin HykesPRES & CEO, Director7,763 shares at $7.90$61,328Mar 2, 202610b5-1 plan
SaleJared OasheimCHIEF FINANCIAL OFFICER1,744 shares at $7.90$13,778Mar 2, 202610b5-1 plan
SalePaul VerrastroCHIEF MKTG & STRAT OFFICER1,284 shares at $7.90$10,144Mar 2, 202610b5-1 plan
SaleRobert Allen JohnChief Revenue Officer3,964 shares at $7.90$31,316Mar 2, 202610b5-1 plan
BuyMudit K. JainDirector2× since Feb 18, 2026: 47,400 shares, avg. $6.34$300,432Feb 20, 2026
SaleJohnson & Johnson Innovation - JJDC, Inc.10% owner22,337 shares at $10.03$224,040Nov 26, 2025
Sale& Johnson Johnson10% owner3× since Nov 12, 2025: 10,037 shares, avg. $10.03$100,692Nov 26, 2025
Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.4%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−190.2% (2020) → −90.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside+56.5% · Top 25%
Profitability
Return on assets−50.9% · Bottom 25%
Net margin (12 months)−88.3% · Bottom 25%
Operating margin (12 months)−94.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−5.8% · Bottom 25%
Balance sheet
Debt / equity1.26× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CVRx Inc Fair Value". https://www.fairvalue-calculator.com/stock/CVRX
Frequently asked questions
Is CVRx Inc (CVRX) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $1.36 versus a price of $0.8690, about +57% upside (undervalued).
What is the fair value of CVRX?
Our model-based fair value for CVRx Inc is $1.36 (as of Nov 8, 2026), built from audited fundamentals. The current price: $0.8690.
What is the quality score of CVRX?
CVRx Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CVRx Inc (CVRX)?
Our model-based price target is the fair value of $1.36 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $0.9000, optimistic scenario $1.70. It is a calculation from audited fundamentals, not an analyst target.
What is the CVRx Inc stock forecast for 2026?
Our models put fair value at $1.36, about +57% upside versus a price of $0.8690 (undervalued). Cautious scenario $0.9000, optimistic scenario $1.70. The calculation is refreshed regularly with new filings.
What is the revenue of CVRx Inc (CVRX)?
CVRx Inc reported trailing-twelve-month revenue of about $60.3M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of CVRx Inc (CVRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CVRx Inc it is $1.36 per share (as of Nov 8, 2026), against a price of $0.8690. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is CVRx Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, CVRX trades below its calculated fair value: price $0.8690, fair value $1.36, a gap of about +57% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CVRX?
No. The price is what the market pays today ($0.8690); the fair value is what the company's own numbers justify ($1.36). For CVRx Inc the two are $0.4910 per share apart. That gap is exactly why we show both numbers side by side.
How much is CVRx Inc worth?
The market values CVRx Inc at about $23.0M (market capitalisation, as of Nov 8, 2026). Per share that is $0.8690; our models calculate a fair value of $1.36 per share.
What do the bullish and bearish scenarios say about CVRX?
Our models span a range for CVRx Inc: cautious scenario $0.9000, base $1.36, optimistic $1.70 per share (as of Nov 8, 2026, price $0.8690). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CVRx Inc (CVRX)?
Balance-sheet figures for CVRx Inc (as of Nov 8, 2026): return on equity −172.2%, debt of 1.26 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is CVRX from its 52-week high?
CVRx Inc trades at $0.8690, about 91% below its 52-week high of $10.05 and at the low of $0.8690 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $1.36 is for.
Which stocks are comparable to CVRx Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CVRx Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $0.8690, calculated fair value $1.36 (+57%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CVRX calculated?
We run CVRx Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $1.36 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. CVRx Inc currently trades 36% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CVRx Inc (CVRX)?
The closing price on Nov 6, 2026 was $0.8690. Our model-based fair value is $1.36, about +57% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CVRx Inc right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.9000). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.9000 to $1.70) leaves room in how you read the outcome.
Key figures of CVRx Inc
How large is the market capitalisation of CVRx Inc (CVRX)?
The market capitalisation of CVRx Inc is $23.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CVRx Inc (CVRX)?
The price-to-sales ratio of CVRx Inc is 0.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CVRx Inc (CVRX)?
Earnings per share at CVRx Inc are $−2.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CVRx Inc (CVRX)?
The net margin of CVRx Inc is −88.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CVRx Inc (CVRX)?
The return on equity (ROE) of CVRx Inc is −172% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CVRx Inc (CVRX)?
On an EBIT basis the return on assets of CVRx Inc is −36.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CVRx Inc (CVRX)?
The operating margin of CVRx Inc is −94.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CVRx Inc (CVRX)?
Revenue at CVRx Inc is growing −5.8% versus a year earlier (3y avg +36.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CVRx Inc (CVRX) generate?
The free cash flow of CVRx Inc is −$40.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CVRx Inc (CVRX) hold?
CVRx Inc holds more cash than debt, $24.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch CVRx Inc in the live analysis
One click puts CVRx Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
